1. Home
  2. FBDT vs JSPR Comparison

FBDT vs JSPR Comparison

Compare FBDT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FBDT

First Breach Inc. Common Stock

N/A

Current Price

$0.89

Market Cap

32.2M

Sector

Industrials

ML Signal

N/A

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.63

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBDT
JSPR
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.2M
26.3M
IPO Year
2026
2019

Fundamental Metrics

Financial Performance
Metric
FBDT
JSPR
Price
$0.89
$0.63
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
6.5M
448.0K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.32
52 Week High
$1.25
$2.69

Technical Indicators

Market Signals
Indicator
FBDT
JSPR
Relative Strength Index (RSI) 60.70 41.43
Support Level $0.71 $0.55
Resistance Level $1.25 $1.01
Average True Range (ATR) 0.14 0.06
MACD 0.02 -0.01
Stochastic Oscillator 44.06 28.89

Price Performance

Historical Comparison
FBDT
JSPR

About FBDT First Breach Inc. Common Stock

First Breach Inc is an American defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing unmanned aerial systems for commercial, law enforcement, and military markets. Its ammunition operations include the in-house production of brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition. The company is also developing U.S.-made unmanned aerial systems incorporating robotics, intelligence, surveillance and reconnaissance (ISR), sensor, and precision manufacturing technologies for defense, homeland security, law enforcement, and commercial applications.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: